About the Respimat Inhaler
The RESPIMAT inhaler was designed to get the medicine deep into patients’ lungs. The RESPIMAT inhaler operates independent of inspiratory effort and the slow-moving mist helps patients inhale the medicine.
As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as coordination between actuation of the inhaler and inspiration through the delivery system. The duration of inhalation should be at least as long as the spray duration (1.5 seconds).
Boehringer Ingelheim’s RESPIMAT family of products includes five FDA-approved medicines for respiratory diseases.
About HealthPrize Technologies
Life science companies worldwide use HealthPrize’s technology to develop digital patient experiences that enhance revenue by improving adherence, increasing health literacy, and providing brand differentiation. The company’s gamification- and behavioral economics-based platform powers and advances patient engagement for branded and generic medications across all therapeutic areas, demographics and drug delivery methods.
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.
Padilla, for HealthPrize Technologies
Associate Director, Communications
Boehringer Ingelheim Pharmaceuticals, Inc.